Open Journal of Urology, 2021, 11, 393-403 https://www.scirp.org/journal/oju ISSN Online: 2160-5629 ISSN Print: 2160-5440 DOI: 10.4236/oju.2021.1111038 Nov. 17, 2021 393 Open Journal of Urology The Impact of 18F-DCFPyL PSMA PET-CT in the Management of Prostate Cancer Biochemical Recurrence Raquel García 1 , Virginia Morillo 2 , Pablo Sopena 3 , Miguel R. Soler 1 , María Rodríguez 1 , Ana Aliaga 1 , Laura Moral 1 , Carlos M. Martínez 3 , Eduardo Ferrer 1 , Carlos Ferrer 2 1 Radiation Oncology, University Clinical Hospital, Valencia, Spain 2 Radiation Oncology, Provincial Hospital Consortium, Castellón, Spain 3 Nuclear Medicine, Vithas Hospital October 9, Valencia, Spain Abstract Purpose: We evaluated the findings from 18F-DCFPyL PSMA PET-CTs per- formed on patients presenting biochemical recurrence (BCR) of prostate cancer (PCa) and assessed its impact on staging. Methods and materials: This was a multicenter retrospective analysis of patients with PCa and BCR who underwent 18F-DCFPyL PSMA PET-CT in 2020. The patients were stratified into two groups: BCR after prostatectomy (PSA ≥ 0.2 ng/mL) or BCR after radiotherapy (PSA ≥ 2 ng/mL + nadir). We analyzed the lesions according to number and location. The Shapiro-Wilk test was used to estimate the distri- bution of the variables. We calculated representative statistics for the quantit- ative variables including the mean, standard deviation, median, and inter- quartile range. The association between qualitative variables was examined using Chi-squared tests. Results: 40 patients with BCR were analyzed; 67.5% presented disease progression, predominantly distant recurrence (42.5%), which was found exclusively in bone; 55% presented ≤5 lesions and of these, 68.2% only presented 1 lesion. There was a change in staging in 66.7% of the cases; 17.7% received ablative treatment with stereotactic radiotherapy (SABR). Con- clusions: 18F-DCFPyL PSMA PET-CT represents a new way to manage pa- tients with BCR that, in this study, resulted in a change in staging in 66.7% of cases and early identification of oligometastatic progressions in the subgroup of patients with PSA < 0.5 ng/mL. Keywords Prostate Specific Membrane Antigen, Prostate Cancer, PET-CT PSMA 18F-DCFPyL, Biochemical Recurrence How to cite this paper: García, R., Moril- lo, V., Sopena, P., Soler, M.R., Rodríguez, M., Aliaga, A., Moral, L., Martínez, C.M., Ferrer, E. and Ferrer, C. (2021) The Impact of 18F-DCFPyL PSMA PET-CT in the Management of Prostate Cancer Biochem- ical Recurrence. Open Journal of Urology, 11, 393-403. https://doi.org/10.4236/oju.2021.1111038 Received: October 17, 2021 Accepted: November 14, 2021 Published: November 17, 2021 Copyright © 2021 by author(s) and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY 4.0). http://creativecommons.org/licenses/by/4.0/ Open Access